I don’t remember the details of the rhb-104 study design, but I think they were testing the patients for map infection. If, when the results are published, we don’t see an impressive response and remission rate with those who were tested positive, that would be very disappointing - primarily because that would imply the falsity of the map hypothesis as the etiology of Crohn’s disease. That’s because this study and the treatment is designed very well; unlike the Selby et al. study.
Post Edited (xy123) : 5/17/2018 7:33:34 AM (GMT-6)